Automate Your Wheel Strategy on GILD
With Tiblio's Option Bot, you can configure your own wheel strategy including GILD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GILD
- Rev/Share 23.1823
- Book/Share 15.7357
- PB 7.1631
- Debt/Equity 1.2679
- CurrentRatio 1.3154
- ROIC 0.149
- MktCap 140459342891.0
- FreeCF/Share 7.5253
- PFCF 14.9919
- PE 22.3315
- Debt/Assets 0.4477
- DivYield 0.0277
- ROE 0.3294
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | GILD | Daiwa Securities | Neutral | Outperform | -- | $128 | Aug. 19, 2025 |
| Upgrade | GILD | Truist | Hold | Buy | -- | $127 | Aug. 8, 2025 |
| Upgrade | GILD | Needham | Hold | Buy | -- | $133 | July 25, 2025 |
| Resumed | GILD | Cantor Fitzgerald | -- | Overweight | -- | $125 | April 22, 2025 |
| Reiterated | GILD | Oppenheimer | -- | Outperform | $115 | $132 | March 4, 2025 |
| Upgrade | GILD | Deutsche Bank | Hold | Buy | -- | $120 | Feb. 18, 2025 |
| Upgrade | GILD | DZ Bank | Hold | Buy | -- | $108 | Feb. 13, 2025 |
| Upgrade | GILD | Morgan Stanley | Equal Weight | Overweight | $87 | $113 | Jan. 10, 2025 |
| Resumed | GILD | BofA Securities | -- | Buy | -- | $109 | Dec. 10, 2024 |
| Upgrade | GILD | Leerink Partners | Market Perform | Outperform | $74 | $96 | Oct. 21, 2024 |
News
Levi & Korsinsky Investigates Possible Securities Fraud by Gilead Sciences, Inc. (GILD)
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning possible violations of federal securities laws. Gilead issued a press release on June 10, 2025, announcing that "[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]" specifying that "[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte …
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ:GILD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Negative
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
Read More
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (NASDAQ:GILD ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET Company Participants Daniel P. O'Day - Chairman & CEO Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great.
Read More
Gilead shares fall after FDA places clinical hold on HIV treatment trials
Published: June 10, 2025 by: Proactive Investors
Sentiment: Negative
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) dropped up to 4% on Tuesday following an announcement that the US Food and Drug Administration (FDA) has placed clinical holds on studies involving two of the company's investigational HIV drugs. The FDA's clinical hold affects trials of GS-1720, an integrase strand transfer inhibitor, and GS-4182, a capsid inhibitor.
Read More
US FDA places clinical hold on 2 Gilead trials of weekly HIV pill combination
Published: June 10, 2025 by: Reuters
Sentiment: Negative
The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of its experimental HIV treatments, the company said on Tuesday.
Read More
Gilead Sciences, Inc. (GILD) Jefferies Global Healthcare Conference (Transcript)
Published: June 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (NASDAQ:GILD ) Jefferies Global Healthcare Conference June 4, 2025 11:05 PM ET Company Participants Cindy Perettie - Executive Vice President of Kite Dietmar P. Berger - Chief Medical Officer Conference Call Participants Michael Jonathan Yee - Jefferies LLC, Research Division Michael Jonathan Yee Good morning, everyone.
Read More
Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard care.
Read More
Put Cash To Work: 2 Magnificent Dividends I'm Betting On
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Positive
High-quality assets like RTX and AbbVie are ideal for growth and income, offering inflation resilience and strong shareholder returns. RTX has a robust $217B backlog, rising global defense spending, robust margins, and a 32-year dividend growth streak, justifying its GARP valuation. AbbVie is rapidly replacing Humira revenue with high-growth drugs, maintains industry-leading margins, and delivers a 3.5% yield with double-digit EPS growth potential.
Read More
Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However, we recommend investors remain on the sidelines at current levels.
Read More
Gilead Sciences, Inc. (GILD) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Published: May 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (NASDAQ:GILD ) Bernstein Annual Strategic Decisions Conference May 29, 2025 2:30 PM ET Company Participants Dan O'Day - Chairman and Chief Executive Officer Conference Call Participants Courtney Breen - Bernstein Courtney Breen All right. Wonderful.
Read More
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Read More
Gilead Sciences' Best Days May Be Ahead - Here's Why
Published: May 26, 2025 by: Seeking Alpha
Sentiment: Positive
Despite a sharp decline in sales of COVID-19 blockbuster Veklury, Gilead Sciences once again beat consensus revenue and EPS forecasts. The drugs whose performance impressed me greatly in Q1 2025 and which played a key role in maintaining Gilead's EBIT margin above 38% are Biktarvy, Livdelzi, and Yescarta. Meanwhile, the sales dynamics of its oncology franchise left me with mixed feelings, including due to the increasing pressure from more effective CAR T-cell therapies, bispecific antibodies, and ADCs.
Read More
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Gileads Trodelvy shows significant improvement in PFS in phase III ASCENT-03 trial for first-line metastatic TNBC, reinforcing potential as backbone therapy.
Read More
ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy® (sacituzumab govitecan-hziy). The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not candidates for PD-1/PD-L1 inhibitor.
Read More
Gilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference (Transcript)
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (NASDAQ:GILD ) RBC Capital Markets Global Healthcare Conference May 21, 2025 11:30 AM ET Company Participants Cindy Perettie - Executive Vice President of Kite Conference Call Participants Brian Abrahams - RBC Capital Markets Brian Abrahams Represented by their Executive Vice President of Kite, Cindy Perettie, who is in charge of running their CAR-T franchise. So Cindy, thanks so much for joining us.
Read More
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
Gilead Sciences, Inc. GILD and GSK GSK are pioneers in the human immunodeficiency virus (HIV) treatment space.
Read More
2 Dividend Stocks That are Holding Their Own in 2025
Published: May 17, 2025 by: 24/7 Wall Street
Sentiment: Positive
Perhaps it's not all too surprising to witness the S&P 500 run into turbulence after two of the best years for stock gains in recent memory.
Read More
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Read More
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated for the treatment of primary biliary cholangitis (PBC) and also provides sustained biochemical response in adults with PBC regardless of prior treatment history. Another analysis provides evidence supporting that Livdelzi delivered clinically and.
Read More
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss?
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Negative
GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the oncology business is under pressure.
Read More
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors
Published: April 29, 2025 by: Reuters
Sentiment: Negative
Gilead Sciences has reached a $202 million settlement to resolve a civil fraud lawsuit accusing the company of paying kickbacks to doctors who agreed to prescribe its HIV drugs, the U.S. attorney's office in Manhattan said on Tuesday.
Read More
Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions
Published: April 29, 2025 by: CNBC
Sentiment: Negative
Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions
Read More
GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Negative
Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down.
Read More
Gilead says Trodelvy-Keytruda combo effective for aggressive breast cancer type
Published: April 21, 2025 by: Reuters
Sentiment: Positive
Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's immunotherapy Keytruda significantly slowed disease progression in patients with an aggressive type of breast cancer.
Read More
About Gilead Sciences, Inc. (GILD)
- IPO Date 1992-01-22
- Website https://www.gilead.com
- Industry Drug Manufacturers - General
- CEO Daniel P. O'Day
- Employees 17600